These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35983952)

  • 21. Adaptive Enrichment Designs in Clinical Trials.
    Thall PF
    Annu Rev Stat Appl; 2021 Mar; 8(1):393-411. PubMed ID: 36212769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient adaptive designs with mid-course sample size adjustment in clinical trials.
    Bartroff J; Lai TL
    Stat Med; 2008 May; 27(10):1593-611. PubMed ID: 18275090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blinded sample size recalculation in multiple composite population designs with normal data and baseline adjustments.
    Gera RG; Friede T
    Biom J; 2023 Oct; 65(7):e2000326. PubMed ID: 37309256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interim decision making in seamless trial designs: An application in an adaptive dose-finding study in a rare kidney disease.
    Papachristofi O; Bornkamp B; Wright M; Friede T
    Pharm Stat; 2024; 23(1):20-30. PubMed ID: 37691560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
    Johnston SE; Lipkovich I; Dmitrienko A; Zhao YD
    Pharm Stat; 2022 Sep; 21(5):1090-1108. PubMed ID: 35322520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample size determination in group-sequential clinical trials with two co-primary endpoints.
    Asakura K; Hamasaki T; Sugimoto T; Hayashi K; Evans SR; Sozu T
    Stat Med; 2014 Jul; 33(17):2897-913. PubMed ID: 24676799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A conditional error function approach for adaptive enrichment designs with continuous endpoints.
    Placzek M; Friede T
    Stat Med; 2019 Jul; 38(17):3105-3122. PubMed ID: 31066093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and monitoring of clinical trials with an interim analysis and a negative binomial endpoint.
    Quan H; Xu Y; Liu Y; Chen X
    Contemp Clin Trials; 2024 Mar; 138():107467. PubMed ID: 38331382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size.
    Antoniou M; Jorgensen AL; Kolamunnage-Dona R
    J Pers Med; 2017 Dec; 7(4):. PubMed ID: 29207572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sample size recalculation in internal pilot study designs: a review.
    Friede T; Kieser M
    Biom J; 2006 Aug; 48(4):537-55. PubMed ID: 16972704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
    Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
    Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive clinical trial designs with pre-specified rules for modifying the sample size: understanding efficient types of adaptation.
    Levin GP; Emerson SC; Emerson SS
    Stat Med; 2013 Apr; 32(8):1259-75; discussion 1280-2. PubMed ID: 23081665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simple procedures for blinded sample size adjustment that do not affect the type I error rate.
    Kieser M; Friede T
    Stat Med; 2003 Dec; 22(23):3571-81. PubMed ID: 14652861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adaptive clinical trials: progress and challenges.
    Coffey CS; Kairalla JA
    Drugs R D; 2008; 9(4):229-42. PubMed ID: 18588354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size reassessment in non-inferiority trials. Internal pilot study designs with ANCOVA.
    Friede T; Kieser M
    Methods Inf Med; 2011; 50(3):237-43. PubMed ID: 20213039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.